Searchable abstracts of presentations at key conferences in endocrinology

ea0008p30 | Diabetes, metabolism and cardiovascular | SFE2004

EPIDEMIOLOGICAL STUDY ON GLYCEMIA CONTROL IN PATIENTS WITH DM1 AND DM2, Epicon study- baseline visit analysis

Sanabria MC , Rodriguez J , Badia X , Novials A

INTRODUCTION:Diabetes Mellitus is one of the most important problems which has greater health care impact in Spain. It is concluded from the DCCT study on DM1 and UKPDS in DM2 that control of HbA1c levels is essential to reduce chronic complications. Guidelines suggest maintaining HbA1c levels below 7%.PATIENTS AND METHODS:Design: Epidemiological, longitudinal, prospective and multicenter study in Spain, with two cohorts, DM1 (n=40...

ea0029p1408 | Pituitary Clinical | ICEECE2012

Pasireotide treatment is associated with clinically meaningful improvements in health-related quality of life in Cushing’s disease: results from a large, randomized, double-blind phase III trial

Webb S , Badia X , Zgliczynski W , Portocarrero-Ortiz L , Maldonado M , Trovato A , Forsythe A , Nelson L , McLeod L , De Block C , Gadelha M

Introduction: Patients with Cushing’s disease have significantly impaired health-related quality of life (HRQoL). Effective treatment is needed to treat Cushing’s disease and improve HRQoL; however, there are currently no approved medical treatments for Cushing’s disease. The effect of pasireotide on HRQoL in patients with Cushing’s disease was evaluated as part of a randomized, phase III study.Methods: Patients with persistent/recurr...

ea0011oc20 | Clinical endocrinology | ECE2006

A European prospective real-life observational study of Quality of Life in patients with acromegaly

Webb SM , Colao A , Caron P , Carvalheiro M , Ertürk E , Pokrajac-Simeunovic A , Schopohl J , Tsagarakis S , Pearson IV , Badia X , Caglio S , Vincenzi B

The primary aim of this study, the largest European, single evaluation, observational trial to date, was to evaluate the impact of acromegaly on health-related quality of life (HRQoL) in patients with biochemically documented active disease, receiving Sandostatin® LAR® at a dose prescribed by their physician for at least 3 months. Secondary objectives were to investigate the relationships between HRQoL and subpopulations based on exploratory var...